Home > Result Summaries: Compounds > casopitant > Result Summary for NKT102553

Result Summary for NKT102553

Result Summary

Protocol ID:	NKT102553
Clinical Study ID:	NKT102553
Official Title:	A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50 mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Phase:	phase 3
Study Indications or Diseases:	Nausea and Vomiting, Postoperative
Generic Name:	casopitant
Trade/Product Name:	Zunrisa,Rezonic
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Altorjay A, Melson T, Chinachoti T, Kett A, Aqua K, Levin J, Blackburn LM, Lane S, Pergolizzi JV. Casopitant and Ondansetron for Postoperative Nausea and Vomiting Prevention in Women at High Risk for Emesis: A Phase 3 Study. [Arch Surg]. 2011;146(2):201-206.